These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1030 related articles for article (PubMed ID: 28427013)

  • 1. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
    Wu J; Savooji J; Liu D
    J Hematol Oncol; 2016 Mar; 9():19. PubMed ID: 26951079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
    Santarpia M; Daffinà MG; D'Aveni A; Marabello G; Liguori A; Giovannetti E; Karachaliou N; Gonzalez Cao M; Rosell R; Altavilla G
    Drug Des Devel Ther; 2017; 11():2047-2063. PubMed ID: 28740365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Millett RL; Elkon JM; Tabbara IA
    Anticancer Res; 2018 Sep; 38(9):4969-4975. PubMed ID: 30194140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
    J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
    Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
    J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.